DOT1L Is a Novel Cancer Stem Cell Target for Triple Negative Breast Cancer

By
Justin.choi
-
0
17
Scientists tested if inhibition of DOT1L, an epigenetic regulator of normal tissue stem/progenitor populations, would target triple negative breast cancers stem cells.
[Clinical Cancer Research]

Sorry, but the selected Zotpress account can't be found.

Abstract